article thumbnail

Sandoz bulks up ahead of possible sale with Coalesce buy

pharmaphorum

This morning, Sandoz announced it has acquired medical and drug delivery device specialist Coalesce Product Development, bolstering its capabilities for the development of respiratory medicines and ‘complex’ generics.

article thumbnail

Astellas loses bid to block Lexiscan generics in US

pharmaphorum

It looks like Astellas has been unsuccessful in its attempt to block Pfizer’s generic medicines unit Hospira from launching a copycat version of big-selling pharmacologic stress agent Lexiscan in the US. The drug was originally developed by CV Therapeutics – bought by Gilead in 2009 – and first launched in the US in 2008.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Astellas facing generics to big-selling Lexiscan product in US

pharmaphorum

Astellas has won a reprieve in its attempt to stop Pfizer’s generic medicines unit Hospira launching a copycat version of its pharmacologic stress agent Lexiscan in the US – but only for a couple of weeks. The post Astellas facing generics to big-selling Lexiscan product in US appeared first on.

article thumbnail

Cerelle vs Cerazette: Are they really the same?

Druggist

As with other drugs, some patients may believe that branded medicine is better than generic medication. Generic medicines are usually much cheaper because they do not go through the same process of marketing authorisation. Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH, Patel DT, Yang Y, Yu LX, Woodcock J (2009).